Home Blog
Credit Suisse successfully concluded the 9th Credit Suisse China Investment Conference (CIC) held in early November in Shenzhen. The central theme of this year’s CIC was assessing China’s state of health – including its economic outlook, the performance of its leading companies and innovators and, pertinently, developments in its healthcare industry.
China has been at the forefront of technological innovation and has achieved impressive progress in strengthening its entrepreneur community and helping people to live smarter, healthier and better lives. In the meantime, Chinese government has been actively encouraging and promoting innovation and business startups, which nurtured a large number of “unicorn” companies, making China now the second-largest source of “unicorns”.
Christian Schmid is Fund Manager for Credit Suisse Asset Management
Vincent Chan is Head of China Equity Strategy Research at Credit Suisse
Kyna Wong is Head of China Technology Research at Credit Suisse
Health is in the spotlight at this year’s Credit Suisse China Investment Conference. This includes the state of China’s economic health, as 40 years on from the beginning of its economic reforms, it faces a range of challenges that threaten its growth and influence. At the same time, the CIC is taking an in-depth look at Chinese healthcare as the country seeks to position its pharmaceutical industry as a global leader while trying to build a system that can support the medical needs of the population.
